Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GalNAc-siCNNM4
- Development stage
- Preclinical
- Lead developer
- Silence Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
GalNAc-siCNNM4 (also referred to as GalNAc-siCnnm4) is a liver-targeted small interfering RNA (siRNA) therapeutic conjugated to N-acetylgalactosamine (GalNAc). It is designed to selectively silence the expression of Cyclin M4 (CNNM4), a magnesium exporter, in hepatocytes. Developed in collaboration with Silence Therapeutics using their proprietary mRNAi GOLD platform, GalNAc-siCNNM4 aims to restore intracellular magnesium homeostasis, alleviate endoplasmic reticulum stress, and reduce inflammation and fibrosis. It is currently in preclinical development for various liver conditions, including metabolic dysfunction-associated steatohepatitis (MASH/NASH), alcohol-associated liver disease (ALD), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and acetaminophen-induced liver injury.
- Other names
- CNNM4 siRNACNNM-4 siRNACNNM 4 siRNAGalNAc-conjugated CNNM4 siRNAGalNAc-siCnnm4GalNAc-siCnnm-4GalNAc-siCnnm 4siCnnm4siCnnm-4siCnnm 4siRNA-CNNM4siRNA-CNNM-4siRNA-CNNM 4
Beyond the preview
Go deeper on GalNAc-siCNNM4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GalNAc-siCNNM4.